v3.26.1
Description of Business (Tables)
9 Months Ended
Apr. 30, 2026
Description of Business [Abstract]  
Schedule of Consolidated Financial Statements

All wholly and majority-owned subsidiaries and RP Finance, LLC are consolidated with all intercompany transactions and balances eliminated in consolidation. In addition to Rafael Holdings, Inc., the entities included in these consolidated financial statements are as follows:

Company  Country of Incorporation 

Percentage
Owned

 
Broad Atlantic Associates, LLC  United States – Delaware   100%
IDT R.E. Holdings Ltd.  Israel   100%
Rafael Holdings Realty, Inc.  United States – Delaware   100%
Barer Institute, Inc.  United States – Delaware   100%*
Hillview Avenue Realty, JV  United States – Delaware   100%
Hillview Avenue Realty, LLC  United States – Delaware   100%
Rafael Medical Devices, LLC  United States – Delaware   73%
Farber Partners, LLC  United States – Delaware   93%
Pharma Holdings, LLC  United States – Delaware   90%**
LipoMedix Pharmaceuticals Ltd.  Israel   95%
Altira Capital & Consulting, LLC  United States – Delaware   67%
CS Pharma Holdings, LLC  United States – Delaware   45%**
Day Three Labs, Inc.  United States – Delaware   84%
Cornerstone Pharmaceuticals, Inc.  United States – Delaware   67%
RP Finance, LLC  United States – Delaware   38%
Cyclo Therapeutics, LLC (Note 3)  United States – Nevada   100%

 

*In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer. The decision was taken to reduce spending as the Company focuses on exploring strategic opportunities.

 

**50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership interest in Pharma Holdings, LLC and, therefore, an effective 45% economic interest in CS Pharma Holdings, LLC. The Company, along with CS Pharma Holdings, LLC and Pharma Holdings LLC, collectively own securities representing 67% of the outstanding capital stock of Cornerstone.